Petition to expedite FDA approval of MCO-010 for Retinitis Pigmentosa, a rare disease
Petition to expedite FDA approval of MCO-010 for Retinitis Pigmentosa, a rare disease
The Issue
RETINITIS PIGMENTOSA (RP), a rare disease, and related retinal abnormalities are devastating genetic disorders affecting over **1 in 4,000 people worldwide**, leading to progressive vision loss and eventual blindness. There are **no FDA-approved treatments** to halt or reverse this condition.
#LightForRP # PriorityReviewBLA #ApproveMCO010 #RareDisease
Patients face:
- **Physical challenges**: Loss of independence, mobility, and ability to perform daily tasks.
- **Psychological suffering**: Depression, anxiety, and isolation due to irreversible vision loss.
- **Financial burden**: Costs of assistive devices, caregivers, and lost productivity.
MCO-010, developed by Nanoscope Therapeutics, represents a **transformative breakthrough**. As a **broad-spectrum optogenetic therapy**, it has the potential to restore functional vision across diverse genetic mutations, offering hope where none currently exists.
We respectfully urge the FDA to:
1. **Expedite the priority review** the priority review of the Biological License Application (BLA) for MCO-010.
2. **Prioritize approval** of this therapy to address the urgent unmet medical need.
3. **Engage collaboratively** with Nanoscope Therapeutics to streamline the regulatory process without compromising safety.
**Every day without treatment deepens the crisis for millions living in darkness.**
SUPPORTING FACTS
- **Clinical Promise**: MCO-010 has demonstrated success in early trials, restoring light sensitivity and functional vision in blind patients.
- **Broad Applicability**: Unlike gene-specific therapies, MCO-010 works independent of genetic mutations, making it accessible to a wide population.
- **Global Impact**: Over 2 million people worldwide suffer from RP and related retinal disorders.
Submitted By:
** The Global Retinitis Pigmentosa (RP) and Genetic Retinal Disorders Patients Community**
**WE, THE UNDERSIGNED, URGENTLY REQUEST THE FDA TO PRIORITIZE THE REVIEW AND APPROVAL OF MCO-010, A GROUNDBREAKING OPTOGENETIC THERAPY FOR IRREVERSIBLE VISION IMPAIRMENT AND BLINDNESS.**
4,757
The Issue
RETINITIS PIGMENTOSA (RP), a rare disease, and related retinal abnormalities are devastating genetic disorders affecting over **1 in 4,000 people worldwide**, leading to progressive vision loss and eventual blindness. There are **no FDA-approved treatments** to halt or reverse this condition.
#LightForRP # PriorityReviewBLA #ApproveMCO010 #RareDisease
Patients face:
- **Physical challenges**: Loss of independence, mobility, and ability to perform daily tasks.
- **Psychological suffering**: Depression, anxiety, and isolation due to irreversible vision loss.
- **Financial burden**: Costs of assistive devices, caregivers, and lost productivity.
MCO-010, developed by Nanoscope Therapeutics, represents a **transformative breakthrough**. As a **broad-spectrum optogenetic therapy**, it has the potential to restore functional vision across diverse genetic mutations, offering hope where none currently exists.
We respectfully urge the FDA to:
1. **Expedite the priority review** the priority review of the Biological License Application (BLA) for MCO-010.
2. **Prioritize approval** of this therapy to address the urgent unmet medical need.
3. **Engage collaboratively** with Nanoscope Therapeutics to streamline the regulatory process without compromising safety.
**Every day without treatment deepens the crisis for millions living in darkness.**
SUPPORTING FACTS
- **Clinical Promise**: MCO-010 has demonstrated success in early trials, restoring light sensitivity and functional vision in blind patients.
- **Broad Applicability**: Unlike gene-specific therapies, MCO-010 works independent of genetic mutations, making it accessible to a wide population.
- **Global Impact**: Over 2 million people worldwide suffer from RP and related retinal disorders.
Submitted By:
** The Global Retinitis Pigmentosa (RP) and Genetic Retinal Disorders Patients Community**
**WE, THE UNDERSIGNED, URGENTLY REQUEST THE FDA TO PRIORITIZE THE REVIEW AND APPROVAL OF MCO-010, A GROUNDBREAKING OPTOGENETIC THERAPY FOR IRREVERSIBLE VISION IMPAIRMENT AND BLINDNESS.**
4,757
The Decision Makers
Supporter Voices
Petition Updates
Share this petition
Petition created on March 9, 2025